状核在阿尔茨海默氏病中表现出明显的病理和细胞类型特定的反应
bioRxiv : the preprint server for biology
|January 16, 2026
概括
阿尔茨海默氏病 (AD) 病理在尾状核显示独特的特征,如线和粉样斑块. 与皮层不同,神经元数量保持稳定,但其他细胞类型和内神经元显示出显著的变化.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 神经病理学神经病理学
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β (Aβ) 和酸化 (pTau) 病理.
- 尾状核 (Ca) 在较晚的AD阶段 (Thal阶段III) 受到影响,但其细胞病理学尚不清楚.
- 之前的研究集中在皮质AD病理上,使得像Ca这样的皮质下区域没有得到充分的描述.
研究的目的:
- 在尾状核中创建AD相关的病理变化的细胞分辨率图谱.
- 为了研究AD病理的特定细胞影响在Ca.
- 将Ca中的AD细胞病理与皮层区域中观察到的细胞病理进行比较.
主要方法:
- 为细胞群体分析利用了一个公共的基底性腺分类学.
- 在加拿大产生了AD病理学的细胞分辨率图谱.
- 分析了针对AD病理的细胞比例和基因表达的变化.
主要成果:
- 在Ca中,AD病理的特征是,pTau神经线靠近寡干细胞和灰质中的分散的Aβ斑块.
- 在Ca中没有观察到AD驱动的神经元比例的减少,与皮质AD形成鲜明对比.
- 原生态星体细胞和特定的微质细胞 (FLT1+/IL1B+) 与pTau水平增加;快速升的内部神经元显示基因表达改变.
结论:
- 与皮质相比,尾状核表现出明显的细胞AD病理概况.
- 阿尔茨海默病不会减少Ca中的神经元数量,但会改变质和内部神经元的数量.
- 这项研究为了解尾状核中的AD提供了一个细胞框架.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825


